Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Hiroko Iizuka-Honma"'
Autor:
Hiroko Iizuka-Honma, Haruko Takizawa, Toru Mitsumori, Hidehiro Okura, Hisato Ishii, Masaaki Noguchi
Publikováno v:
Internal Medicine. 62:459-463
Publikováno v:
Journal of Clinical and Experimental Hematopathology. 63:32-36
Autor:
Haruko Takizawa, Yoshihiko Araki, Maki Fujishiro, Shigeki Tomita, Satsuki Kishikawa, Akane Hashizume, Toru Mitsumori, Hideaki Nitta, Hiroko Iizuka-Honma, Tomohiro Sawada, Mitsuo Okubo, Yasunobu Sekiguchi, Miki Ando, Masaaki Noguchi
Publikováno v:
Journal of Clinical and Experimental Hematopathology.
Publikováno v:
The American journal of hospicepalliative care.
Background Clinicians can appropriately terminate treatment or reduce treatment intensity by determining prognostic factors of end-of-life chemotherapy. In particular, it provides important information for patients with hematological malignancies who
Autor:
Hiroko, Iizuka-Honma, Haruko, Takizawa, Toru, Mitsumori, Hidehiro, Okura, Hisato, Ishii, Masaaki, Noguchi
Publikováno v:
Internal medicine (Tokyo, Japan).
Many patients with primary vitreoretinal lymphoma (PVRL) exhibit central nervous system (CNS) involvement either at the diagnosis or during follow-up. The prognosis in the patients of PVRL with relapsed or refractory CNS remains extremely poor. We he
Publikováno v:
JCO oncology practice. 18(1)
PURPOSE: Uncertainty of prognosis is one reason patients with hematologic malignancies receive aggressive therapy near end of life more often than those with advanced solid tumors. It is unknown whether end-of-life prognosis prediction models are use
Publikováno v:
JCO Oncology Practice; Jan2022, Vol. 18 Issue 1, p75-e116, 10p